Difference between revisions of "Tumour regression"
Jump to navigation
Jump to search
| (10 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Tumour regression''' can occur as a consequence of treatment | '''Tumour regression''' can occur (1) sporadically, or (2) as a consequence of treatment (treatment response). | ||
==Sporadic tumour regression== | ==Sporadic tumour regression== | ||
| Line 6: | Line 6: | ||
*[[Malignant melanoma]]. | *[[Malignant melanoma]]. | ||
*[[Neuroblastoma]]. | *[[Neuroblastoma]]. | ||
May occur in: | |||
*[[Basal cell carcinoma]].<ref name=Ref_Derm476>{{Ref Derm|476}}</ref> | |||
Note: | |||
*Melanocytic lesions in general, ''not'' only melanoma, may regress.<ref name=Ref_Derm476>{{Ref Derm|476}}</ref><ref name=pmid21029398>{{Cite journal | last1 = Speeckaert | first1 = R. | last2 = van Geel | first2 = N. | last3 = Vermaelen | first3 = KV. | last4 = Lambert | first4 = J. | last5 = Van Gele | first5 = M. | last6 = Speeckaert | first6 = MM. | last7 = Brochez | first7 = L. | title = Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. | journal = Pigment Cell Melanoma Res | volume = 24 | issue = 2 | pages = 334-44 | month = Apr | year = 2011 | doi = 10.1111/j.1755-148X.2010.00799.x | PMID = 21029398 }}</ref> | |||
==Microscopic== | ==Microscopic== | ||
| Line 12: | Line 18: | ||
*+/-Mucin. | *+/-Mucin. | ||
*+/-Inflammation. | *+/-Inflammation. | ||
*+/-Histiocytes. | |||
Note: | |||
*There are specific criteria for ''[[malignant melanoma]]''. | |||
===Grading of tumour regression=== | ===Grading of tumour regression=== | ||
There is a three tiered regression grading system by Ryan ''et al''.<ref name=pmid16045774>{{Cite journal | last1 = Ryan | first1 = R. | last2 = Gibbons | first2 = D. | last3 = Hyland | first3 = JM. | last4 = Treanor | first4 = D. | last5 = White | first5 = A. | last6 = Mulcahy | first6 = HE. | last7 = O'Donoghue | first7 = DP. | last8 = Moriarty | first8 = M. | last9 = Fennelly | first9 = D. | title = Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. | journal = Histopathology | volume = 47 | issue = 2 | pages = 141-6 | month = Aug | year = 2005 | doi = 10.1111/j.1365-2559.2005.02176.x | PMID = 16045774 }}</ref> | ====Colorectal carcinoma==== | ||
{{Main|Colorectal carcinoma}} | |||
There is a three tiered regression grading system by Ryan ''et al''. for [[colorectal cancer]].<ref name=pmid16045774>{{Cite journal | last1 = Ryan | first1 = R. | last2 = Gibbons | first2 = D. | last3 = Hyland | first3 = JM. | last4 = Treanor | first4 = D. | last5 = White | first5 = A. | last6 = Mulcahy | first6 = HE. | last7 = O'Donoghue | first7 = DP. | last8 = Moriarty | first8 = M. | last9 = Fennelly | first9 = D. | title = Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. | journal = Histopathology | volume = 47 | issue = 2 | pages = 141-6 | month = Aug | year = 2005 | doi = 10.1111/j.1365-2559.2005.02176.x | PMID = 16045774 }}</ref> | |||
====Esophageal carcinoma==== | |||
*The three tier system from Ryan ''et al.'' for colorectal cancer has been applied to esophageal carcinomas.<ref>{{cite journal |authors=Takeda FR, Tustumi F, de Almeida Obregon C, Yogolare GG, Navarro YP, Segatelli V, Sallum RAA, Junior UR, Cecconello I |title=Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus |journal=Ann Surg Oncol |volume=27 |issue=4 |pages=1241–1247 |date=April 2020 |pmid=31664618 |doi=10.1245/s10434-019-07967-8 |url=}}</ref> | |||
====Ovarian carcinoma==== | |||
{{Main|Ovarian carcinoma}} | |||
This has been examined by McCluggage ''et al.''<ref name=pmid11825920>{{Cite journal | last1 = McCluggage | first1 = WG. | last2 = Lyness | first2 = RW. | last3 = Atkinson | first3 = RJ. | last4 = Dobbs | first4 = SP. | last5 = Harley | first5 = I. | last6 = McClelland | first6 = HR. | last7 = Price | first7 = JH. | title = Morphological effects of chemotherapy on ovarian carcinoma. | journal = J Clin Pathol | volume = 55 | issue = 1 | pages = 27-31 | month = Jan | year = 2002 | doi = | PMID = 11825920 }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 17:57, 14 March 2021
Tumour regression can occur (1) sporadically, or (2) as a consequence of treatment (treatment response).
Sporadic tumour regression
Well-known:
May occur in:
Note:
Microscopic
Features:
- +/-Fibrosis.
- +/-Mucin.
- +/-Inflammation.
- +/-Histiocytes.
Note:
- There are specific criteria for malignant melanoma.
Grading of tumour regression
Colorectal carcinoma
Main article: Colorectal carcinoma
There is a three tiered regression grading system by Ryan et al. for colorectal cancer.[4]
Esophageal carcinoma
- The three tier system from Ryan et al. for colorectal cancer has been applied to esophageal carcinomas.[5]
Ovarian carcinoma
Main article: Ovarian carcinoma
This has been examined by McCluggage et al.[6]
References
- ↑ Balzer, BL.; Ulbright, TM. (Jul 2006). "Spontaneous regression of testicular germ cell tumors: an analysis of 42 cases.". Am J Surg Pathol 30 (7): 858-65. doi:10.1097/01.pas.0000209831.24230.56. PMID 16819328.
- ↑ 2.0 2.1 Busam, Klaus J. (2009). Dermatopathology: A Volume in the Foundations in Diagnostic Pathology Series (1st ed.). Saunders. pp. 476. ISBN 978-0443066542.
- ↑ Speeckaert, R.; van Geel, N.; Vermaelen, KV.; Lambert, J.; Van Gele, M.; Speeckaert, MM.; Brochez, L. (Apr 2011). "Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy.". Pigment Cell Melanoma Res 24 (2): 334-44. doi:10.1111/j.1755-148X.2010.00799.x. PMID 21029398.
- ↑ Ryan, R.; Gibbons, D.; Hyland, JM.; Treanor, D.; White, A.; Mulcahy, HE.; O'Donoghue, DP.; Moriarty, M. et al. (Aug 2005). "Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer.". Histopathology 47 (2): 141-6. doi:10.1111/j.1365-2559.2005.02176.x. PMID 16045774.
- ↑ Takeda FR, Tustumi F, de Almeida Obregon C, Yogolare GG, Navarro YP, Segatelli V, Sallum RAA, Junior UR, Cecconello I (April 2020). "Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus". Ann Surg Oncol 27 (4): 1241–1247. doi:10.1245/s10434-019-07967-8. PMID 31664618.
- ↑ McCluggage, WG.; Lyness, RW.; Atkinson, RJ.; Dobbs, SP.; Harley, I.; McClelland, HR.; Price, JH. (Jan 2002). "Morphological effects of chemotherapy on ovarian carcinoma.". J Clin Pathol 55 (1): 27-31. PMID 11825920.